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Abstract: Approximately one quarter of patients with breast cancer demonstrate amplification 
of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with 
a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, 
a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, 
has been shown to be biologically active and of considerable clinical utility in HER2-positive 
breast cancer patients. Neoadjuvant chemotherapy has been used in breast cancer to downstage 
the tumor and increase the opportunity for breast-conserving surgery. Preoperative chemotherapy 
can also serve as an in vivo testing of chemotherapy sensitivity. Additionally, a pathologic com-
plete response is usually a surrogate marker of disease-free survival. Following the successful 
use of trastuzumab in the metastatic and adjuvant settings, many clinical trials have recently 
reported the successful use of anti-HER2 therapy in combination with different chemotherapy 
regimens in the neoadjuvant setting with a significantly higher pathologic complete response. 
With the recent introduction of new anti-HER2 drugs, interest has shifted toward dual HER2 
blockade. Two such studies were recently reported, both showing a significant advantage of 
dual anti-HER2 therapy using lapatinib or pertuzumab in addition to trastuzumab and chemo-
therapy. However, several key questions need to be investigated further, such as the preferred 
combination chemotherapy and the optimal duration of trastuzumab in patients who achieve a 
pathologic complete response following preoperative chemotherapy with trastuzumab. These 
issues and others are discussed in this review.
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Introduction
Neoadjuvant therapy, also known as primary systemic treatment, was initially intro-
duced for the treatment of inoperable locally advanced or inflammatory breast cancer. 
Increasingly, primary systemic treatment is now considered for women with large but 
operable disease. The rationale of this approach is to provide early chemotherapy that 
allows theoretical downstaging of the tumor, higher rates of breast-conserving sur-
geries. and in vivo testing of tumor response to the chosen chemotherapy.1–5 Despite 
the various definitions of pathologic complete response in the neoadjuvant trials, the 
correlation of pathologic complete response with improved disease-free survival and 
overall survival has already been demonstrated in several studies and is currently used 
as a surrogate marker for chemotherapy benefit in the neoadjuvant setting.6–8
Neoadjuvant chemotherapy has been compared with adjuvant chemotherapy using 
the same drug regimens in patients with operable breast cancer, with no difference 
in overall survival or disease-free survival. In the National Surgical Adjuvant Breast Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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and Bowel Project (NSABP) B18 trial, patients with clinical 
T1-3, N0-1 breast cancer were randomly assigned to neo-
adjuvant or adjuvant chemotherapy utilizing four cycles of 
adriamycin + cyclophosphamide. There was no statistically 
significant difference between neoadjuvant and adjuvant 
chemotherapy in nine-year overall survival.9 At 16 years of 
follow-up, the difference in overall survival between the two 
groups remained statistically insignificant (hazard ratio [HR] 
0.99; 95% confidence interval [CI] 0.85–1.16).10
Similar conclusions were reached utilizing different 
chemotherapy regimens. The European Organisation for 
Research and Treatment of Cancer 10902 trial random-
ized patients with clinical T1c–T4b breast cancer to neo-
adjuvant or adjuvant chemotherapy with four cycles of 
  fluorouracil + epirubicin + cyclophosphamide. At a median 
follow-up of 56 months, there was no significant difference 
between neoadjuvant and adjuvant chemotherapy in terms of 
four-year overall survival (82% versus 84%) or progression-
free survival (65% versus 70%).11
Many neoadjuvant clinical trials have been reported 
utilizing different chemotherapeutic agents, the more recent 
of which have utilized taxanes (paclitaxel or docetaxel) and 
anthracyclines (adriamycin [doxorubicin] or   epirubicin) 
in their regimens. The NSABP B27 trial utilized four 
cycles of adriamycin + cyclophosphamide with or with-
out four cycles of docetaxel, with the surgery performed 
before or after the docetaxel. Compared with preopera-
tive adriamycin + cyclophosphamide alone, preoperative 
adriamycin + cyclophosphamide followed by docetaxel 
increased the clinical complete response rate (40.1% ver-
sus 63.6%; P , 0.001), the overall clinical response rate 
(85.5% versus 90.7%; P , 0.001), the pathologic complete 
response rate (13.7% versus 26.1%; P , 0.001), and the 
proportion of patients with negative nodes (50.8% versus 
58.2%; P , 0.001).12 Similar results were also achieved 
in the Aberdeen trial utilizing different docetaxel-based 
neoadjuvant chemotherapy.13
Approximately one quarter of patients with breast   cancer 
demonstrate overamplification of the human epidermal 
receptor type 2 (HER2) gene, resulting in an overexpres-
sion of the HER2 receptor, a transmembrane tyrosine 
kinase receptor, the activation of which is known to result 
in increased activity of a variety of molecular pathways 
associated with tumor growth and progression.14 Extensive 
published data have demonstrated that patients whose 
  cancers overexpress HER2 have a relatively poor prognosis 
independent of other clinical and pathologic variables, like 
tumor size and nodal status.15–17
Trastuzumab, a humanized recombinant monoclonal 
antibody specifically directed against the HER2 receptor, 
has been shown to be biologically active and of considerable 
clinical utility in HER2-positive breast cancer patients.18 
Trastuzumab was approved by the US Food and Drug 
Administration in 1998 after a landmark Phase III trial in 
women with HER2-positive metastatic breast cancer showed 
dramatic improvement in overall response rates and overall 
survival with the addition of trastuzumab to standard first-
line chemotherapy consisting of doxorubicin + cyclophos-
phamide or paclitaxel.19 Many Phase II trials have reported 
similar clinical benefit when this drug is combined with a 
number of other chemotherapeutic agents including doc-
etaxel, vinorelbine, capecitabine, and gemcitabine, in both 
front-line and pretreated metastatic settings.20–25
So far, the results of five Phase III randomized trials 
exploring the benefit of adding trastuzumab to adjuvant 
chemotherapy for early HER2-positive breast cancer patients 
have been reported.26–31 All trials demonstrated significant 
improvement in disease-free survival. The HERA (Herceptin 
Adjuvant) trial26,27 and the joint analysis of two other studies, 
NSABP B31 and North Central Cancer Treatment Group 
N31,30 also showed an improved overall survival.
The encouraging data from published clinical trials 
resulted in enormous interest in incorporating trastuzumab 
into the neoadjuvant setting in women with HER2-positive 
breast cancer, hoping to improve the outcome of such 
patients. The present paper reviews the present clinical trials 
in this regard and outline the main results and their impact 
on clinical practice.
First randomized trial
The use of concurrent chemotherapy and trastuzumab in 
the preoperative setting has been investigated in several 
studies. In one of the initial trials, Buzdar et al from the MD 
Anderson Cancer Center randomized patients with HER2-
positive, early-stage operable breast cancer to receive four 
cycles of paclitaxel every three weeks followed by four 
cycles of   fluorouracil + epirubicin + cyclophosphamide with 
or without concomitant weekly trastuzumab. The addition 
of trastuzumab to neoadjuvant chemotherapy significantly 
increased the pathologic complete response rate from 26.3% 
in the chemotherapy arm alone to 65.2% in the trastuzumab 
arm (P = 0.016).32 The study was closed prematurely after 
recruiting only 42 patients, and a third, open-label, nonran-
domized cohort (n = 22) was added to the study, and all were 
assigned to the trastuzumab arm. Among the 45 patients who 
received chemotherapy plus trastuzumab, the pathologic Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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complete response rate was 60% (95% CI 44.3–74.3). Both 
the   one-year, disease-free survival rate (100% versus 94.7% 
in the chemotherapy plus trastuzumab and chemotherapy 
alone arms, respectively) and the three-year, disease-free 
survival rate (100% versus 85.3%, respectively) improved 
with the addition of trastuzumab which was significant 
(P = 0.041) among the randomized arms.33 However, the 
addition of trastuzumab to neoadjuvant therapy had a minimal 
effect on the rate of breast-conserving therapy performed 
(52.6% and 56.5% of patients in the chemotherapy alone and 
chemotherapy with trastuzumab arms, respectively).
Larger Phase III trials
The use of trastuzumab was also assessed in larger clinical 
trials in patients with newly diagnosed locally advanced 
or inflammatory breast cancer. The NOAH (Neoadjuvant 
Herceptin) trial was a large, international Phase III trial 
designed to assess the efficacy and safety of sequential 
doxorubicin + paclitaxel followed by paclitaxel, then cyclo-
phosphamide + methotrexate + 5-fluorouracil with (n = 117) 
or without (n = 118) concomitant trastuzumab, in patients 
with newly diagnosed locally advanced breast cancer. A 
third arm of patients (n = 99) with HER2-negative disease 
who received the same regimen but without trastuzumab 
was also included. Patients with HER2-positive disease 
who received neoadjuvant chemotherapy with concurrent 
trastuzumab had a significantly improved overall response 
rate (87% versus 74%; P = 0.009) and pathologic complete 
response rate in breast tissue (43% versus 22%; P = 0.0007) 
compared with those who received neoadjuvant chemo-
therapy alone. A significant improvement in the pathologic 
complete response rate was also observed in a subgroup 
analysis of patients with inflammatory breast cancer who 
received trastuzumab compared with those who did not (39% 
versus 20%; P = 0.002). At a median follow-up of 3.2 years, 
the three-year, event-free survival improved significantly in 
patients with HER2-positive disease who received chemo-
therapy plus trastuzumab compared with those who received 
chemotherapy alone (71% versus 56%, HR 0.59; P = 0.013). 
For HER2-positive patients, the three-year overall survival 
of trastuzumab arm as compared with chemotherapy alone 
arm was 87% (95% CI 79–92) and 79% (95% CI 70–86), 
respectively (P = 0.114).34
The German Breast Group/Gynecologic Oncology Study 
Group (GeparQuattro) trial was also designed to evaluate the 
effect of trastuzumab on pathologic complete response rates 
in a group of 1509 patients with either locally advanced (T3 or 
T4), hormone receptor-negative or hormone   receptor-positive 
but lymph node-positive tumors. All patients were   scheduled 
to receive four cycles of epirubicin 90 mg/m2 and cyclo-
phosphamide 600 mg/m2 and were then randomly assigned 
to three treatment arms; the first arm received four cycles of 
docetaxel 100 mg/m2 (EC-D), the second arm received four 
cycles of docetaxel 75 mg/m2 + capecitabine 1800 mg/m2 
(EC-DX) while the third arm received four cycles of doc-
etaxel 75 mg/m2 followed by four cycles of capecitabine 
1800 mg/m2 on days 1–14 (EC-D-X). In each arm, patients 
with HER2-positive disease received trastuzumab start-
ing from the initiation of the EC for 52 weeks. Patients 
with HER2-negative tumors received chemotherapy only. 
In total, 445 patients with HER2-positive tumors were 
included. Pathologic complete response rate, defined as no 
invasive or in situ residual tumors in the breast, was 31.7% 
for patients who had received neoadjuvant trastuzumab plus 
chemotherapy and 15.7% for patients who received chemo-
therapy alone (P , 0.001). In the HER2-positive group, a 
pathologic complete response was observed in 48 (32.9%) of 
146 patients treated with EC-D, 45 (31.3%) of 144 patients 
treated with EC-DX, and 47 (34.6%) of 136 patients treated 
with EC-D-X. The rate of breast-conserving surgery was 
comparable among patients in the HER2-positive group 
(63.1%) and the HER2-negative reference group (64.7%).35 
Results of these major trastuzumab-based neoadjuvant trials 
are summarized in Table 1.
Newer anti-HER2 drugs
The HER family consists of four transmembrane receptors 
that mediate a complex network of signaling pathways,36 and 
HER1, HER2, and HER3 are all implicated in the develop-
ment and progression of cancer.37 While the role of the HER4 
receptor in breast cancer is unclear, the HER3 receptor is 
gaining increasing interest in cancer research.38
Ligand binding to the extracellular domain of the HER 
receptor initiates a conformational rearrangement, expos-
ing the dimerization (receptor pairing) domain that forms 
the core of the dimer interface with another HER receptor. 
HER2 has no identified ligands and exists in an open confor-
mation that allows dimerization with other HER receptors.39 
HER2 and HER3 are highly complementary to each other, 
ie, HER3 binds ligand yet lacks intrinsic kinase activity while 
HER2 has intrinsic tyrosine kinase activity but no identified 
ligand.36 HER2 dimerizes preferentially with HER3 to drive 
downstream signaling.40,41
Pertuzumab is the first of a new class of targeted anti-
cancer agents known as the HER2 dimerization inhibitors.42 
It is a humanized monoclonal antibody that binds to the Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
90
Abdel-Razeq and Marei
  dimerization domain of HER2, which is an extracellular 
region essential for HER activation and signaling. The 
mechanism of action of pertuzumab, ie, inhibition of HER2 
dimerization, is unique compared with that of other HER-
targeted therapies.43 By blocking the pairing of the most potent 
signaling HER dimer, ie, HER2:HER3, pertuzumab affects 
key signaling pathways that mediate cell proliferation and 
survival in some cancers such as the breast.44 In vitro and in 
vivo studies has shown that pertuzumab works synergistically 
with trastuzumab to inhibit breast tumor cells survival.39–44
Lapatinib is an orally active small molecule which revers-
ibly inhibits both HER1 and HER2 tyrosine kinase domains. 
This concurrent inhibition in HER1-expressing and HER2-
expressing tumors blocks the activating signaling cascades 
in the MAPK and PI3 K pathways, resulting in growth arrest 
and/or apoptosis, as shown in cell line and xenograft models.45 
As a single agent, lapatinib has efficacy similar to that of 
trastuzumab monotherapy in the first-line treatment of HER2-
positive metastatic breast cancer, and was approved by the US 
Food and Drug Administration in 2006 based on a Phase III 
trial demonstrating improved progression-free survival with 
the combination of lapatinib and capecitabine compared with 
capecitabine alone in patients with trastuzumab-refractory 
disease.46 Because lapatinib is a small molecule that can 
penetrate the blood–brain barrier, it is now being extensively 
studied for the treatment and prevention of central nervous 
system metastasis.
Dual anti-HER2 blockade
With the recent introduction of new anti-HER2 drugs, interest 
was shifted toward dual HER2 blockade. The initial results of 
the Neo-ALTTO trial were recently presented at the 33rd San 
Antonio Breast Cancer Symposium.47 The study included 450 
HER2-positive patients who had tumors that were 2 cm or 
larger in diameter and were randomly assigned to one of three 
arms, ie, lapatinib, trastuzumab, or the combination of both. 
Anti-HER2 therapy alone was given for six weeks, and then 
weekly paclitaxel was added for 12 weeks followed by surgery 
at week 18. Following surgery, patients received three cycles 
of fluorouracil + epirubicin + cyclophosphamide were then 
continued on the same anti-HER2 therapy that they were on 
previously for up to a year. The overall response rate was 
significantly higher with lapatinib plus trastuzumab versus 
trastuzumab alone after six weeks and at the time of surgery. 
The pathologic complete response with the combination of 
lapatinib and trastuzumab was 51.3% compared with 29.5% 
for trastuzumab (P = 0.0001). The overall response rate for 
the lapatinib alone arm was 52.6% while 24.7% achieved a 
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pathologic complete response. Although no significant cardiac 
toxicity was reported, patients in the lapatinib arm suffered 
more toxicity than those in the trastuzumab arm including an 
increased incidence of diarrhea, hepatotoxicity, neutropenia, 
and skin disorders. More patients discontinued treatment 
because of adverse events with combination therapy. This 
concept of dual anti-HER2 therapy is being tested in the adju-
vant setting in the ALTTO trial which is about to conclude, 
having accrued its target of 8200 patients.48
The other major dual anti-HER-2 neoadjuvant trial is 
NeoSphere, which looked at a combined blockade using 
trastuzumab + pertuzumab versus trastuzumab alone. This 
study was unique in including an arm that did not receive 
any chemotherapy, just the dual blockade. In this study, 
which was also presented at the 33rd San Antonio Breast 
Cancer Symposium, women with operable, locally advanced, 
or inflammatory breast cancer were randomized to receive 
four cycles every three weeks of docetaxel + trastuzumab 
or docetaxel + trastuzumab + pertuzumab. The other two 
arms received docetaxel + pertuzumab or the doublet of the 
two monoclonal antibodies, trastuzumab a+ pertuzumab, 
without chemotherapy. After surgery, all patients received 
three cycles of fluorouracil + epirubicin + cyclophosph-
amide + trastuzumab every three weeks for one full year. The 
pathologic complete response rate was 45.8% for the com-
bined regimen of two monoclonals compared with 29% for 
the trastuzumab arm (P = 0.014) and 24% for the pertuzumab 
arm (P = 0.003). The pathologic complete response in women 
who received the two monoclonals without chemotherapy 
was 16.8%, thus raising the question whether a subgroup 
of breast cancer patients can be treated with monoclonal 
agents and thus avoid chemotherapy. One patient developed 
congestive heart failure with trastuzumab and pertuzumab.49 
Results of these dual anti-HER2 blockade neoadjuvant trials 
are summarized in Table 2.
Significance of pathologic complete 
response
Pathologic complete response has been almost universally 
adopted in the neoadjuvant trials as a reliable endpoint and 
has been shown to correlate with both disease-free survival 
and overall survival in many of these trials.10,12,50 However, 
the precise definition among different trials varies; earlier 
trials referred to pathologic complete response as absent 
tumor histologically in both the breast and axilla. Later, it 
was regarded as absence of tumor cells in breast tissues only. 
In addition, some trials looked at both invasive and nonin-
vasive (carcinoma in situ) components in the residual tumor 
following the neoadjuvant therapy.
Several trials have shown that the extent of residual breast 
cancer burden and lymph node metastases correlates with 
disease-free survival. In one trial, Hennessy et al reviewed 
response data for 925 patients treated in five prospective 
neoadjuvant trials, including 403 patients with cytologically 
confirmed axillary lymph node metastases. Eighty-nine 
patients (22%) achieved a pathologic complete response in 
the axillary lymph nodes following neoadjuvant therapy. 
The outcome for patients who achieved axillary lymph node 
pathologic complete response with neoadjuvant chemo-
therapy was compared with those having residual disease in 
the axillary lymph nodes. Median follow-up was 64 (range 
15–178) months. The five-year overall survival and relapse-
free survival rates were significantly better in patients with 
a pathologic complete response in the axillary lymph nodes 
(93% [95% CI 87.5–98.5] and 87% [95% CI 79.7–94.3] 
  versus 72% [95% CI 66.5–77.5] and 60% [95% CI 
54.1–65.9], respectively; P , 0.0001).51
Updated follow-up data from both the NSABP-B18 and 
B27 trials have shown similar trends.10 The TECHNO trial 
also addressed this issue after neoadjuvant chemotherapy and 
trastuzumab. In this trial, over 200 HER2-positive patients 
Table 2 Summary of pCR with dual anti-HER2 blockade in neoadjuvant breast cancer trials
Trial Chemotherapy regimens Patients pCR P value
Neo-ALTTO47
Lapatinib + paclitaxel 154 24.7%
0.0001* Trastuzumab + paclitaxel 149 29.5%
Lapatinib + trastuzumab + paclitaxel 152 51.3%
Trastuzumab + docetaxel 107 29% **
Pertuzumab + docetaxel 96 24% 0.03
NeoSphere49 Trastuzumab + pertuzumab + docetaxel 107 45.8% 0.014
Trastuzumab + pertuzumab 107 16.8% 0.031
Notes: *P values as compared with trastuzumab + paclitaxel; **P values as compared with trastuzumab + docetaxel. Neo-ALTTO: lapatinib 1500 mg/day, if combined 
with trastuzumab 1000 mg/day, reduced to 750 mg/day with paclitaxel in 2008. Paclitaxel 80 mg/m2/week. Trastuzumab 4 mg/kg loading then 2 mg/kg/week. NeoSphere: 
pertuzumab 840 mg loading dose and 420 mg maintenance; trastuzumab 8 mg/kg loading dose and 6 mg/kg maintenance; docetaxel 75 mg/m2 with escalation to 100 mg/m2 
if the starting dose was well tolerated.
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received neoadjuvant epirubicin + cyclophosphamide for four 
cycles every three weeks followed by paclitaxel 175 mg/m2 
once every three weeks + trastuzumab 6 mg/kg every three 
weeks after a loading dose of 8 mg/kg. Chemotherapy was 
followed by surgery. Trastuzumab was continued after 
surgery until completion of 12 months of treatment. The 
three-year median follow-up data were recently presented and 
showed a three-year, disease-free survival of 88% compared 
with a rate of 73% among the patients who failed to achieve 
pathologic complete response (P = 0.011). Similarly, overall 
survival was also better (96%) compared with a rate of 86% 
(P = 0.025).52
Cardiac toxicity
Cardiac toxicity was an unexpected finding during the clini-
cal development of trastuzumab. Therefore, baseline cardiac 
evaluation or prospective monitoring were not mandated in 
early clinical trials in the metastatic setting. Also, patients 
with underlying cardiac disease were not excluded. In the 
adjuvant setting, trastuzumab was associated with a low but 
real risk of severe congestive heart failure or cardiac death, 
ranging from 0.6% in the HERA trial26,27 to 3.9% in NSABP-
B3130 in patients who had prior anthracyclines. The majority 
of the observed trastuzumab-related cardiac events were 
asymptomatic decreases in left ventricular ejection fraction 
(LVEF), and both symptomatic and asymptomatic events 
were largely reversible.
In a meta-analysis including 10,955 patients treated in 
adjuvant trials, the risk of symptomatic, clinically significant 
(grade 3 to 4) heart failure following one year of trastuzumab 
versus chemotherapy not containing trastuzumab was 1.9% 
versus 0.3%, while the risk of an asymptomatic decrease in 
LVEF in patients treated with trastuzumab versus no trastu-
zumab was 13.3% versus 6.1%.53
Simultaneous administration of trastuzumab + epirubicin 
in the MD Anderson Cancer Center study has raised the 
concern for cardiac toxicity. Among patients randomized 
to fluorouracil + epirubicin + cyclophosphamide and tras-
tuzumab, the median LVEF decreased from 65% to 60% by 
the end of follow-up, but the LVEF range remained nearly 
constant. None of the 45 patients treated with chemotherapy 
and trastuzumab in the initial and the assigned cohort experi-
enced clinical cardiac dysfunction, and there were no cardiac 
deaths in this study.32
In the GeparQuattro Study, congestive heart failure and 
cardiac ischemia were reported in two patients each treated 
with chemotherapy alone and in one patient treated with 
chemotherapy and trastuzumab. A decrease in LVEF to 45% 
was reported in five patients and an LVEF decrease of more 
than 10% from baseline was reported in two patients treated 
with trastuzumab.32 Similar trends were also noted in the 
NOAH trial.34
The risk of cardiac toxicity can be reduced by close 
cardiac monitoring during therapy and by avoiding treat-
ing patients with a baseline LVEF , 50%. Older patients 
with baseline LVEF 50%–55% and cardiac risk factors 
such as smoking, hypertension, body mass index . 25, 
and diabetes mellitus should be treated cautiously with 
close cardiac surveillance. Extending the window between 
the completion of anthracycline chemotherapy and initia-
tion of trastuzumab, and administering trastuzumab with 
a nonanthracycline chemotherapy regimen may be a good 
option for high-risk patients with underlying cardiac dis-
ease or borderline LVEF. Biomarkers such as troponin and 
brain natriuretic peptide are being explored as potential 
early markers of cardiac injury, as is the prophylactic use 
of cardiac medications.54
Future directions
A larger randomized Phase III clinical trial, ie, NSABP-B41, 
is currently ongoing to evaluate pathologic complete response 
rate with the administration of adriamycin + cyclophosph-
amide followed by weekly paclitaxel in combination with 
trastuzumab, lapatinib, or a combination of both trastu-
zumab and lapatinib, in the preoperative setting for patients 
with palpable and operable HER-2 positive breast cancer 
(NCT00486668).55
There is growing interest in identifying biologic mark-
ers that would help tailoring treatment to individuals by 
recognizing reliable response predictors. Such markers may 
be related to cell proliferation, cell cycles, angiogenesis, or 
signal transduction. In the previously discussed NeoSphere 
study, tumor and blood specimens from .95% of patients 
have been collected and are being probed.49
HER2-specific vaccines are an interesting new concept 
that have been evaluated in preclinical studies, with the 
hypothesis that generation of an anti-HER2 immune response 
may lead to slower tumor development at early stages. 
  Different vaccine strategies are being tested.56
Several other key questions need to be investigated fur-
ther, such as the preferred chemotherapy for combination 
with trastuzumab (anthracycline versus nonanthracycline-
based therapy) and the optimal duration of trastuzumab 
in patients who achieve pathologic complete response 
after preoperative chemotherapy with trastuzumab. 
Lastly, a randomized clinical trial comparing the benefit Biologics: Targets and Therapy 2011:5 submit your manuscript | www.dovepress.com
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of trastuzumab in combination with chemotherapy in the 
preoperative versus postoperative setting is also needed 
to determine the best strategy to administer trastuzumab-
based chemotherapy.
Conclusion
Many good quality clinical studies suggest that trastuzumab 
should be incorporated in the preoperative treatment of 
women with HER2-positve disease, a fact that is already 
incorporated into the current National Comprehensive Cancer 
Network guidelines. As discussed in this paper, several key 
questions still need to be addressed, including the preferred 
combination chemotherapy and the optimal duration of 
trastuzumab in patients who achieve a complete pathologic 
response after preoperative chemotherapy.
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